Sports specialist Macron sees surging revenues as Europe, UK and US boom
It saw total revenues of €107 million, up from €93 million for the same period last year and only €79 million in H1 2023. The Bologna-based firm's H1 revenue rise was 14.7% year on year for the half and 30% on a two-year basis.
And for the full year it expects record revenues. It didn't put a monetary figure or percentage on that but last year's annual revenue reached €223.6 million.
Its sales are increasingly derived from markets outside of Italy and as well as the UK being hugely important to it, the company has seen 'significant growth' in Germany and the US.
And it added that growth has also been driven by investments in the Macron Campus with construction having begun on the fourth building that will further increase the company's overall operational capacity.
For instance, German revenues rose 45% in the period and US revenues — while coming from a low starting point — were up by an even bigger percentage. They rose from €1.4 million in H1 2024 to €5.4 million in H1 2025. That was helped by the opening of the new distribution centre in Connecticut in 2024, which it said 'further demonstrates Macron's ability to achieve its growth objectives even in macroeconomic environments marked by volatility'.
It's also a further sign of how smaller players in the sportswear market are challenging the dominance of much bigger global names.
CEO Gianluca Pavanello said: 'The results achieved in the first half once again confirm the soundness of our growth path and the value of the strategic choices made in recent years, particularly in terms of internationalisation and our unwavering commitment to product quality.
'Our expansion into complex markets shows that our model based on innovation, sporting passion and attention to detail is appreciated worldwide. At the same time, the ongoing investments in the Macron Campus are essential to supporting this growth: we want to keep improving, looking to the future with ambition, convinced that beautiful things are created in beautiful places.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Network
an hour ago
- Fashion Network
India accuses EU, US of double standard over Russian trade
India has sharply criticised the US and the European Union, saying it is being unfairly singled out by them over its Russian oil purchases when they both trade extensively with Moscow despite the war in Ukraine. India's criticism followed a renewed threat by US President Donald Trump on Monday to raise tariffs on goods from India over its Russian oil purchases, deepening the trade rift between the two countries. In a rare show of unity, Prime Minister Narendra Modi's Bharatiya Janata Party (BJP) and the main opposition Congress on Tuesday condemned Trump's repeated criticism of New Delhi. India's Foreign Ministry said in a statement issued late on Monday that "it is revealing that the very nations criticising India are themselves indulging in trade with Russia". The US embassy and the EU's delegation in New Delhi did not immediately respond to a request for comment. Both the US and EU have sharply scaled back their trade ties with Russia since it launched a full-scale invasion of Ukraine in February 2022. In 2021, Russia was the EU's fifth-largest trading partner, with goods exchange worth 258 billion euros, according to the EU executive European Commission. The sudden rift between India and the US has been deepening since July 31, when Trump announced a 25% tariff on Indian goods being shipped to the US and for the first time threatened unspecified penalties for buying Russian oil. India is one of the biggest buyers of crude from Russia, importing about 1.75 million barrels per day from January to June this year, up 1% from a year ago. India has said it does not support "unilateral sanctions" by the EU. Trade experts say Trump's tariff could badly hurt India's economy. Ajay Srivastava of the New Delhi-based Global Trade Research Initiative said he expected Indian goods exports to the US to fall 30% in the current fiscal year ending March 31, to 60.6 billion dollars from 86.5 billion dollars in the 2025 fiscal year. India's equity benchmarks fell after Trump's renewed threat of harsh tariffs on goods from India. Manish Tewari, a member of parliament and Congress leader, said Trump's "disparaging remarks hurt the dignity and self-respect of Indians". "The time has come to call out this constant bullying and hectoring," he added. BJP Vice President Baijayant Jay Panda quoted Henry Kissinger - the most powerful US diplomat of the Cold War era - in a post on X: "To be an enemy of America can be dangerous, but to be a friend is fatal."
Euronews
an hour ago
- Euronews
EU Commission 'surprised' by German minister's jibe on trade deal
The European Commission said on Tuesday it was surprised by comments German Finance Minister Lars Klingbeil in which he highlighted the EU's weakness in the ongoing tariff talks, despite Germany having been fully briefed ahead of the agreement reached on July 27 by Commission President Ursula von der Leyen and US President Donald Trump. 'It is most surprising to us,' Commission spokesperson Olof Gill said, adding: 'Nothing has happened here in terms of the Commission's approach, negotiation or outcome achieved without the clear signal received from our member states.' Klingbeil said on Monday, ahead of his meeting with US Treasury Secretary Scott Besant in Washington DC, that EU representatives 'have shown weakness' during trade negotiations with the US. 'Overall, as Europeans, we must become stronger," Klingbeil insisted, "then we can also stand up to the US with more self-confidence. Not against the US, but in dialogue with the US.' Germany 'had been fully briefed on the details of the agreement at a political level', Commission Deputy Spokesperson Arianna Podestà added on Tuesday. Since the announcement of the EU-US tariff agreement on July 27, the Commission has maintained that the deal represents the least bad option, allowing the EU to avoid a further escalation in the transatlantic trade dispute. However, the details of the agreement are still under negotiation, just days after a US Executive Order set tariffs at 15%. Germany, in particular, continues to see its automotive industry heavily impacted by 25% US tariffs — contrary to the political deal, which aimed to reduce them to 15%. Negotiations also continue on which products may be eligible for exemptions. 'We fight for every product and every industry,' a senior EU official said, adding: 'We're really trying to get as many products into the list of exemptions.' A joint EU-US statement is expected to be released soon, aiming to reinforce the political commitments made on both sides of the Atlantic. Under the current framework, the US has agreed to apply a 15% tariff on EU goods, while the EU has committed to purchasing US energy and investing in the United States.
Euronews
2 hours ago
- Euronews
Pfizer earnings strong despite Trump's new 'up to 250%' tariff threat
Pharmaceutical giant Pfizer reported better-than-expected quarterly results on Tuesday and improved its predictions for full-year profits, beating Wall Street expectations. The New York-based company reported second-quarter sales of $14.7 billion (€12.74bn) and earnings per share of $0.51 (€0.44). As of around 16.00 CEST, Pfizer shares were up over 4% at $24.58. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," chairman and CEO Albert Bourla said in a statement. "We continue to be actively engaged with policymakers as we navigate a complicated and rapidly evolving geopolitical environment while also remaining focused on advancing our business," Bourla continued. This despite several policies announced by the current US administration that could hurt drugmakers. In May, US President Donald Trump signed an executive order whereby pharmaceutical companies would be compelled to lower prices based on a "Most Favored Nation" policy. The price-slashing scheme seeks to ban drug companies from selling products in the US at prices above those in other developed countries. In Europe, the comparison becomes complex, as a significant portion pharmaceutical costs are covered by national healthcare or insurance systems, lowering prices for consumers. Experts warned at the time that this could slash their US revenues and affect availability. Even so, the president doubled down on his plans, sending letters last week to 17 drugmakers, calling for concrete steps to cut prices by 29 September. That includes agreeing to provide their full portfolio of existing medicines at no higher than European prices to every single Medicaid patient. On Tuesday, in an interview with CNBC, he announced that tariffs for pharmaceuticals and semiconductors would be coming in "next week". 'We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," he told CNBC.
